Clinical trial
The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With…
NCT00163059 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00163059 |
|---|---|
| Title | The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD |
| Official title | A Randomized, Double-Blinded, Placebo-Controlled Trial To Assess The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With Treatment Refractory Major Depressive Disorder |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Depressive Disorder, Major |
| Intervention type | Drug |
| Interventions | NMDA Antagonist, CP-101, 606 (traxoprodil) |
| Enrollment | 30 |
| Start date | May 1, 2004 |
| Completion | Dec 1, 2005 |
| First posted | Sep 13, 2005 |
| Last update posted | Sep 22, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: